Novartis reported that the Phase 3 studies of pelacarsen and del-desiran ended without success.
Following the announcement, Novartis shares slid in trading.
Further verified details were not immediately available.
Novartis suffers back-to-back Phase 3 clinical trial failures for pelacarsen and del-desiran, sending shares sliding.
Novartis announced that its Phase 3 trials for pelacarsen and del-desiran did not succeed, causing its share price to fall.
SL
Sophie Laurent · FX & Rates Desk · 19 Sept 2026 · 08:34 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
